suggested that the superior clinical outcome seen in patients with lymphoma harboring high affinity CD16 158 genotypes (V/F or V/V), compared to the low-affinity genotype (F/F), may be due to a quicker NK cells activation in subjects with the CD16 V/V genotype after treatment with rituximab (151). The gene discussed is FCGR3A; the disease is lymphoma.